An SJ - Search Results

1

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL. Cheng H, et al. Among authors: an sj. Cancer Chemother Pharmacol. 2011 Mar;67(3):637-46. doi: 10.1007/s00280-010-1347-4. Epub 2010 May 22. Cancer Chemother Pharmacol. 2011. PMID: 20495920

2

KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer.

An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie Z, Chen SL, Huang Y, Zhang AY, Yan JF, Wu HS, Lin JY, Li R, Zhang XC, Guo AL, Mok TS, Wu YL. An SJ, et al. J Cancer Res Clin Oncol. 2007 Sep;133(9):635-42. doi: 10.1007/s00432-007-0214-0. Epub 2007 May 4. J Cancer Res Clin Oncol. 2007. PMID: 17479290

3

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.

Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. Nie Q, et al. Among authors: an sj. Eur J Pharmacol. 2007 Sep 10;570(1-3):175-81. doi: 10.1016/j.ejphar.2007.05.015. Epub 2007 Jun 5. Eur J Pharmacol. 2007. PMID: 17597605 Clinical Trial.

4

[Association of XAGE-1b gene expression with clinical characteristics of non-small cell lung cancer].

Zhou Q, Guo AL, An SJ, Xu CR, Yang SQ, Wu YL. Zhou Q, et al. Among authors: an sj. Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jul;27(7):966-8. Nan Fang Yi Ke Da Xue Xue Bao. 2007. PMID: 17666327 Chinese.

5

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.

Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, Guo AL, Zhang YF, An SJ, Mok TS, Wu YL. Zhu JQ, et al. Among authors: an sj. Cancer Lett. 2008 Jul 8;265(2):307-17. doi: 10.1016/j.canlet.2008.02.064. Epub 2008 Apr 14. Cancer Lett. 2008. PMID: 18407408

6

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.

Li R, An SJ, Chen ZH, Zhang GC, Zhu JQ, Nie Q, Xie Z, Guo AL, Mok TS, Wu YL. Li R, et al. Among authors: an sj. Hum Pathol. 2008 Dec;39(12):1792-801. doi: 10.1016/j.humpath.2008.05.008. Epub 2008 Aug 19. Hum Pathol. 2008. PMID: 18715616

7

The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer.

An SJ, Chen ZH, Lin QX, Su J, Chen HJ, Lin JY, Wu YL. An SJ, et al. BMC Cancer. 2009 May 12;9:144. doi: 10.1186/1471-2407-9-144. BMC Cancer. 2009. PMID: 19435508 Free PMC article.

8

Three cases of severe hepatic impairment caused by erlotinib.

Huang YS, An SJ, Chen ZH, Wu YL. Huang YS, et al. Among authors: an sj. Br J Clin Pharmacol. 2009 Sep;68(3):464-7. doi: 10.1111/j.1365-2125.2009.03459.x. Br J Clin Pharmacol. 2009. PMID: 19740406 Free PMC article. No abstract available.

9

An autologous therapeutic dendritic cell vaccine transfected with total lung carcinoma RNA stimulates cytotoxic T lymphocyte responses against non-small cell lung cancer.

Wang K, Zhou Q, Guo AL, Xu CR, An SJ, Wu YL. Wang K, et al. Among authors: an sj. Immunol Invest. 2009;38(7):665-80. doi: 10.1080/08820130903070528. Immunol Invest. 2009. PMID: 19811429

10

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, Zhu M, Zhang X, Wu YL. Zhang X, et al. Mol Cancer. 2010 Jul 13;9:188. doi: 10.1186/1476-4598-9-188. Mol Cancer. 2010. PMID: 20624322 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page